RAW-LABS
RAW Labs , today announced it has completed a USD 5.5M pre-A funding round raising capital from new and existing investors to support the surge in demand for its revolutionary data management solution. The company also announced Lars Farnstrom as its new CEO.
The financing round was led by a group of investors specializing in investments of high growth technology companies and Investiere.ch. The funding will enable RAW Labs to accelerate the acquisition of large enterprise clients and continue investing in the expansion of the capabilities of its core NoDB data platform. Claude Honegger (former global CIO of Credit Suisse) and Pyrros Koussios (former private equity investor and senior executive at international technology companies) are joining the board of directors.
“We are excited that Lars has accepted the CEO role. His long experience in enterprise software from companies like Siebel Systems and C3.ai is a tremendous asset and will enable us to take RAW Labs to the next level,” said Ariel Luedi, one of the founding investors of RAW Labs and former CEO of SAP Hybris. Professor Anastasia Ailamaki, co-founder of RAW Labs, will continue as Chief Scientific Officer with the mission to strengthen the company’s research into groundbreaking data management technologies.
RAW Labs’ NoDB is a platform for data engineers, data scientists, and data analysts to seamlessly access, query, clean, and enhance heterogeneous data sources in near real time and transform them into high-value data products for consumption by analytical tools, ML-models, and enterprise applications.
What makes RAW NoDB unique is its revolutionary query engine, which unlike any other solution in the market uses Category Theory. This gives RAW the unique capability to query large and complex data sources at high performance without the need for any costly and time-consuming ETL/ELT preprocessing or integration with data sources.
“It’s a privilege to have a group of sophisticated investors who have proven experience in helping technology companies scale,” said Lars Farnstrom, CEO of RAW Labs. “Data drives digital transformation. We believe that by eliminating the artificial barrier between operational and analytical data, and by enabling this in record time and without any expensive integrations, RAW Labs can help companies accelerate their digital transformation. Just connect your data sources and start asking questions that will help you unlock new insights on how to reduce costs or increase sales.”
About RAW Labs
RAW Labs, an École Polytechnique Fédérale de Lausanne (EPFL) spinout, helps companies unlock the value of data by providing a single unified platform to effortlessly access and convert any data source into data products for new insights and better decision making, at a fraction of the time and cost of traditional solutions. RAW is available on premise, in the cloud, or in hybrid mode.
For more information, visit https://www.raw-labs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005738/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom